Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL
A look at two under the radar early developments in lymphomas which might have a shot at approval
A look at 6 IO products in the Heme space and what to watch out for.
Some intriguing new developments in DLBCL to watch out for
